Faculty Opinions recommendation of All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740883214.793590025 ◽

2021 ◽

Author(s):

A Koneti Rao ◽

Jordan Senchak

Keyword(s):

High Dose ◽

Phase 2 ◽

Newly Diagnosed ◽

First Line ◽

Open Label ◽

High Dose Dexamethasone ◽

Phase 2 Trial ◽

Trans Retinoic Acid ◽

All Trans Retinoic Acid ◽

Randomised Controlled

Download Full-text

All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00240-4 ◽

2021 ◽

Vol 8 (10) ◽

pp. e688-e699 ◽

Cited By ~ 1

Author(s):

Qiu-Sha Huang ◽

Yi Liu ◽

Jing-Bo Wang ◽

Jun Peng ◽

Ming Hou ◽

...

Keyword(s):

High Dose ◽

Phase 2 ◽

Newly Diagnosed ◽

First Line ◽

Open Label ◽

High Dose Dexamethasone ◽

Phase 2 Trial ◽

Trans Retinoic Acid ◽

All Trans Retinoic Acid ◽

Randomised Controlled

Download Full-text

Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30170-9 ◽

2017 ◽

Vol 4 (10) ◽

pp. e487-e496 ◽

Cited By ~ 7

Author(s):

Fei-Er Feng ◽

Ru Feng ◽

Min Wang ◽

Jia-Min Zhang ◽

Hao Jiang ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Trans Retinoic Acid ◽

All Trans Retinoic Acid ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase

Download Full-text

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(09)70284-0 ◽

2010 ◽

Vol 11 (1) ◽

pp. 29-37 ◽

Cited By ~ 639

Author(s):

S Vincent Rajkumar ◽

Susanna Jacobus ◽

Natalie S Callander ◽

Rafael Fonseca ◽

David H Vesole ◽

...

Keyword(s):

Multiple Myeloma ◽

Randomised Controlled Trial ◽

Low Dose ◽

Controlled Trial ◽

Initial Therapy ◽

High Dose ◽

Newly Diagnosed ◽

Open Label ◽

High Dose Dexamethasone ◽

Randomised Controlled

Download Full-text

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30242-5 ◽

2017 ◽

Vol 18 (5) ◽

pp. 672-681a ◽

Cited By ~ 21

Author(s):

Jesus García-Donas ◽

Albert Font ◽

Begoña Pérez-Valderrama ◽

José Antonio Virizuela ◽

Miquel Ángel Climent ◽

...

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Advanced Urothelial Carcinoma ◽

Randomised Controlled ◽

Line Chemotherapy

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Cited By ~ 2

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Download Full-text

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30675-2 ◽

2019 ◽

Vol 20 (1) ◽

pp. 110-119 ◽

Cited By ~ 51

Author(s):

Giuseppe Lombardi ◽

Gian Luca De Salvo ◽

Alba Ariela Brandes ◽

Marica Eoli ◽

Roberta Rudà ◽

...

Keyword(s):

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Randomised Controlled

Download Full-text

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30561-7 ◽

2016 ◽

Vol 17 (12) ◽

pp. 1661-1671 ◽

Cited By ~ 57

Author(s):

Joel W Neal ◽

Suzanne E Dahlberg ◽

Heather A Wakelee ◽

Seena C Aisner ◽

Michaela Bowden ◽

...

Keyword(s):

Small Cell ◽

Phase 2 ◽

Wild Type ◽

Small Cell Lung ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Third Line ◽

Randomised Controlled ◽

Third Line Treatment

Download Full-text

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30059-0 ◽

2020 ◽

Vol 21 (4) ◽

pp. 593-602 ◽

Cited By ~ 6

Author(s):

Kazuyuki Shimada ◽

Motoko Yamaguchi ◽

Yoshiko Atsuta ◽

Kosei Matsue ◽

Keijiro Sato ◽

...

Keyword(s):

Cell Lymphoma ◽

B Cell Lymphoma ◽

Intrathecal Chemotherapy ◽

High Dose ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Trial ◽

Large B Cell Lymphoma ◽

Dose Methotrexate ◽

Large B Cell

Download Full-text

Eltrombopag and Cyclosporine as First-Line Therapy in Patients with Severe Acquired Aplastic Anemia: A Two-part, 5-year, Single-Arm, Multicenter, Open-label, Phase 2 Trial (SOAR)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.242 ◽

2017 ◽

Vol 17 ◽

pp. S389-S390

Author(s):

Phillip Scheinberg ◽

Joan Maier ◽

Ozlem Ocak Arikan ◽

Carlo Finelli ◽

Junho Jang

Keyword(s):

Aplastic Anemia ◽

Phase 2 ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Phase 2 Trial ◽

Line Therapy ◽

Open Label Phase

Download Full-text